Bavarian Nordic hunts for best covid-19 vaccine production setup – may drop current manufacturer
If Bavarian Nordic successfully takes its covid-19 vaccine to the market, it will need to produce a lot of doses. The company cannot currently complete this task, and is looking for ways to secure its production – without guaranteeing a renewed contract with its current partner AGC Biologics.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Bavarian Nordic cannot exclusively handle production of the company's covid-19 vaccine if and when it is ready for phase III and the subsequent commercialization.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic maintains guidance for 2021
For subscribers
.jpg&w=384&q=75)
